FDA partially clears Curis leukemia trial in second August regulatory win

FDA partially clears Curis leukemia trial in second August regulatory win

Source: 
Pharma Live
snippet: 

On Tuesday, Curis, Inc. announced that the FDA has allowed patient enrollment to resume in the monotherapy phase of its TakeAim Leukemia Phase I/II trial studying emavusertib.